Prostate‐specific membrane antigen‐positron emission tomography/computed tomography (PSMA‐PET/CT)‐guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single‐institution experience and review of the published literature

BJU International - Tập 124 Số S1 - Trang 19-30 - 2019
Wee Loon Ong1,2,3, Tze Lui Koh2, Daryl Lim Joon2, Michael Chao2, Briana Farrugia2, Eddie Lau4,5,6, Vincent Khoo7,4,8, Nathan Lawrentschuk9,10, Damien Bolton9, Farshad Foroudi2
1Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia
2Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Vic., Australia
3School of Clinical Medicine, University of Cambridge, Cambridge, UK
4Department of Medicine, University of Melbourne, Melbourne, Vic, Australia
5Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Vic., Australia
6Department of Radiology, Austin Health, Heidelberg, VIC, Australia
7Department of Medical Imaging and Radiation Sciences, Monash University, Clayton, VIC, Australia
8Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK
9Department of Surgery, Austin Health, Heidelberg, VIC, Australia
10EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, Vic., Australia

Tóm tắt

ObjectivesTo report the outcomes of stereotactic ablative body radiotherapy (SABR) in men with oligometastatic prostate cancer (PCa) diagnosed on prostate‐specific membrane antigen (PSMA)‐positron emission tomography/computed tomography (PET/CT), based on a single‐institution experience and the published literature.Patients and MethodsThis was a retrospective cohort study of the first 20 consecutive men with oligometastatic PCa, treated with SABR in a single institution, who had biochemical recurrence after previous curative treatment (surgery/radiotherapy), had no evidence of local recurrence, were not on palliative androgen deprivation therapy (ADT), and had PSMA‐PET/CT‐confirmed oligometastatic disease (≤3 lesions). These men were treated with SABR to a dose of 30 Gy in three fractions for bone metastases, and 35–40 Gy in five fractions for nodal metastases. The outcomes of interest were: PSA response; local progression‐free survival (LPFS); distant progression‐free survival (DPFS); and ADT‐free survival (ADTFS). A literature review was performed to identify published studies reporting on outcomes of PSMA‐PET/CT‐guided SABR.ResultsIn our institutional cohort, 12 men (60%) had a decline in PSA post‐SABR. One man had local progression 9.6 months post‐SABR, with 12‐month LPFS of 93%. Ten men had distant progression outside of their SABR treatment field, confirmed on PSMA‐PET/CT, with 12‐month DPFS of 62%, of whom four were treated with palliative ADT, two received prostate bed radiotherapy for prostate bed progression (confirmed on magnetic resonance imaging), and four received a further course of SABR (of whom one had further progression and was treated with palliative ADT). At last follow‐up, six men (one with local progression and five with distant progression) had received palliative ADT. The 12‐month ADTFS was 70%. Men with longer intervals between local curative treatment and SABR had better DPFS (P = 0.03) and ADTFS (P = 0.005). Four additional studies reporting on PSMA‐PET/CT‐guided SABR for oligometastatic PCa were identified and included in the review, giving a total of 346 patients. PSA decline was reported in 60–70% of men post‐SABR. The 2‐year LPFS, DPFS and ADTFS rates were 76–100%, 27–52%, and 58–62%, respectively.ConclusionOur results showed that PSMA‐PET/CT could have an important role in identifying men with true oligometastatic PCa who would benefit the most from metastases‐directed therapy with SABR.

Từ khóa


Tài liệu tham khảo

10.1016/j.eururo.2015.07.004

10.1200/JCO.2017.75.4853

10.1016/j.eururo.2018.06.004

10.1200/JCO.1995.13.1.8

10.1016/j.eururo.2014.09.004

10.1111/bju.13616

10.1016/j.eururo.2019.01.049

10.1016/j.ijrobp.2018.08.066

10.1016/j.euo.2018.04.017

10.1186/s12885-017-3341-2

10.1002/ijc.32509

10.1007/s12032-018-1137-0

10.1118/1.3438081

10.1016/j.eururo.2017.02.036

10.1056/NEJMoa1503747

10.1056/NEJMoa1702900

10.1056/NEJMoa1704174

10.1056/NEJMoa1903835

10.1056/NEJMoa1903307

10.1111/bju.12964

10.1111/bju.14374

10.1016/j.radonc.2018.06.027

10.1111/bju.14144

10.1016/S0169-5002(14)70214-4

Thông tin
Thông tin xuất bản

BJU International

Tập 124 Số S1

19-30

Thông tin tác giả